Limpar
6 resultados

Acesso aberto

Tipo do recurso

Ano de criação

Produção nacional

Revisado por pares

Áreas

Idioma

Editores

Artigo Acesso aberto Revisado por pares

Ramaswamy Govindan, Marwan Fakih, T. Price, Gerald S. Falchook, Jayesh Desai, James Kuo, John H. Strickler, John C. Krauss, B. Li, C.S. Denlinger, Greg Andrew Durm, Jude Ngang, Haby Henary, Gataree Ngarmchamnanrith, Erik Rasmussen, Phuong K. Morrow, David S. Hong,

The KRASG12C mutation is found in approximately 14% of lung adenocarcinoma and 11% of NSCLC pts. Currently, no approved therapy targets this mutation. AMG 510 is a novel small molecule that specifically and irreversibly inhibits KRASG12C by locking it in an inactive GDP-bound state. A phase 1, first-in-human, open-label, multicenter study (NCT03600883) is evaluating the safety, tolerability, PK, and efficacy of AMG 510 in adult pts with locally-advanced or metastatic KRASG12C mutant solid tumors, ...

Tópico(s): Colorectal Cancer Treatments and Studies

2019 - Elsevier BV | Journal of Thoracic Oncology

Artigo Revisado por pares

Greg Andrew Durm, Sophia Frentzas, Erik Rasmussen, Saltanat Najmi, Nooshin Hashemi Sadraei,

... of anti-AMG 256 antibodies. Citation Format: Greg Durm, Sophia Frentzas, Erik Rasmussen, Saltanat Najmi, Nooshin Hashemi Sadraei. Design and ...

Tópico(s): Monoclonal and Polyclonal Antibodies Research

2021 - American Association for Cancer Research | Cancer Research

Artigo Acesso aberto

Erik Duval, Eddy Forte, Kris Cardinaels, Bart Verhoeven, Rafaël Van Durm, Koen Hendrikx, M. Wentland Forte, Norbert Ebel, Maciej Macowicz, Ken Warkentyne, Florence Haenni,

... Share on The Ariadne knowledge pool system Authors: Erik Duval Katholieke Univ., Leuven, Belgium Katholieke Univ., Leuven, BelgiumView Profile , Eddy Forte Ecole Polytechnique Fédérale de Lauanne, Switzerland Ecole Polytechnique Fédérale de Lauanne, SwitzerlandView Profile , Kris Cardinaels Katholieke Univ., Leuven, Belgium Katholieke Univ., Leuven, BelgiumView Profile , Bart Verhoeven Katholieke Univ., Leuven, Belgium Katholieke Univ., Leuven, BelgiumView Profile , Rafael Van Durm Katholieke Univ., Leuven, Belgium Katholieke Univ., Leuven, BelgiumView ...

Tópico(s): Data Stream Mining Techniques

2001 - Association for Computing Machinery | Communications of the ACM

Artigo Acesso aberto Revisado por pares

Ramaswamy Govindan, Marwan Fakih, T. Price, Gerald S. Falchook, Jayesh Desai, James Kuo, John H. Strickler, John C. Krauss, B. Li, Crystal S. Denlinger, Greg Andrew Durm, Jude Ngang, Haby Henary, Gataree Ngarmchamnanrith, Erik Rasmussen, Phuong K. Morrow, David S. Hong,

KRASG12C mutation occurs in approximately 13-14% of non-small cell lung cancer (NSCLC). Currently, no approved therapy targets this mutation. AMG 510 is a novel small molecule that specifically and irreversibly inhibits KRASG12C by locking it in the inactive GDP-bound state. This is a phase 1, first-in-human, open-label, multicenter study of AMG 510 in adult patients with advanced KRASG12C mutant solid tumors, including NSCLC, colorectal cancer, and other tumor types. Primary endpoint is safety; ...

Tópico(s): Ferroptosis and cancer prognosis

2019 - Elsevier BV | Journal of Thoracic Oncology

Artigo Acesso aberto Revisado por pares

Ramaswamy Govindan, Marwan Fakih, T. Price, Gerald S. Falchook, Jayesh Desai, James Kuo, John H. Strickler, John C. Krauss, Bob T. Li, C.S. Denlinger, Greg Andrew Durm, Jude Ngang, Haby Henary, Gataree Ngarmchamnanrith, Erik Rasmussen, Phuong K. Morrow, David S. Hong,

Currently, no approved therapy targets KRASG12C mutation, which occurs in approximately 13-14% of non-small cell lung cancer (NSCLC). AMG 510, a novel small molecule, specifically and irreversibly inhibits KRASG12C by locking it in an inactive GDP-bound state. This is a phase 1, first-in-human, open-label, multicenter study of AMG 510 in patients with locally advanced or metastatic KRASG12C mutant solid tumors, including NSCLC. The primary endpoint is safety; key secondary endpoints include objective ...

Tópico(s): Peptidase Inhibition and Analysis

2019 - Elsevier BV | Journal of Thoracic Oncology